Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessandra Emiliani is active.

Publication


Featured researches published by Alessandra Emiliani.


Journal of Cachexia, Sarcopenia and Muscle | 2017

Cancer anorexia: hypothalamic activity and its association with inflammation and appetite‐regulating peptides in lung cancer

Alessio Molfino; A. Iannace; Maria Chiara Colaiacomo; Alessio Farcomeni; Alessandra Emiliani; Gualdi Gf; Alessandro Laviano; Filippo Rossi Fanelli

Energy homeostasis is mediated by the hypothalamus, whose inflammation‐induced functional derangements contribute to the onset of anorexia in cancer. By using functional magnetic resonance imaging (fMRI), we determined the patterns of hypothalamic activation after oral intake in anorexic (A), non‐anorexic (NA) cancer patients, and in controls (C).


The Cardiology | 2010

Cancer Chemotherapy and Cardiovascular Risks: Is Capecitabine-Induced Hypertriglyceridemia a Rare Adverse Effect?

Patrizia Seminara; Tania Losanno; Alessandra Emiliani; Gaia Manna

Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations. Capecitabine is an active drug diffusely utilized in the treatment of various types of tumors, such as breast, colorectal, gastric, head and neck carcinoma. In our experience, capecitabine-induced hypertriglyceridemia does not seem to be a rare adverse effect as it is observed in 10% of treated patients. It is necessary to monitor the lipidic profile of patients treated with capecitabine also in consideration of the frequent presence of comorbidities in cancer populations, the concomitant toxicity related to other drugs used in combination regimens, and cardiovascular effects characteristic of biological target therapy.


ERJ Open Research | 2017

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC

Arsela Prelaj; Sara Elena Rebuzzi; Gabriella Del Bene; Julio Rodrigo Giròn Berrìos; Alessandra Emiliani; Lucilla De Filippis; Alessandra Anna Prete; Silvia Pecorari; Gaia Manna; Carla Ferrara; Daniele Rossini; Flavia Longo

In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined. We evaluated clinical response and survival outcomes of advanced LCNEC treated in first-line therapy compared with SCLC. 72 patients with stage III–IV LCNEC (n=28) and extensive-stage SCLC (ES-SCLC) (n=44) received cisplatin–etoposide with/without thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI). Comparing LCNEC with SCLC, we observed similar response rates (64.2% versus 59.1%), disease control rates (82.1% versus 88.6%), progression-free survival (mPFS) (7.4 versus 6.1 months) and overall survival (mOS) (10.4 versus 10.9 months). TRT and PCI in both histologies showed a benefit in mOS (34 versus 7.8 months and 34 versus 8.6 months, both p=0.0001). LCNEC patients receiving TRT showed an improvement in mPFS and mOS (12.5 versus 5 months, p=0.02 and 28.3 versus 5 months, p=0.004), similarly to ES-SCLC. PCI in LCNEC showed an increase in mPFS (20.5 versus 6.4 months, p=0.09) and mOS (33.4 versus 8.6 months, p=0.05), as in ES-SCLC. Advanced LCNEC treated with SCLC first-line therapy has a similar clinical response and survival outcomes to ES-SCLC. Cisplatin–etoposide is an efficient treatment for large-cell neuroendocrine carcinoma. RT and PCI improve survival. http://ow.ly/sBJo309HG8s


BMC Medical Imaging | 2011

An unusual presentation of multiple cavitated lung metastases from colon carcinoma

Patrizia Seminara; Gaia Manna; Alessandra Emiliani; A. Iannace; Tania Losanno

BackgroundConsolidation with or without ground-glass opacity is the typical radiologic finding of lung metastases of adenocarcinoma from the gastrointestinal tract. Lung excavated metastases from gastrointestinal carcinoma are very rare.Case presentationThe authors describe an unusual presentation of multiple cavitated lung metastases from colon adenocarcinoma and discuss the outcome of a patient. The absence both of symptoms and other disease localizations, the investigations related to different diagnostic hypotheses and the empirical treatments caused a delay in correct diagnosis. Only a transparietal biopsy revealed the neoplastic origin of nodules.ConclusionsThis report demonstrates that although lung excavated metastases are described in literature, initial failure to reach a diagnosis is common. We would like to alert clinicians and radiologists to the possibility of unusual atypical features of pulmonary metastases from colon adenocarcinoma.


Case reports in oncological medicine | 2013

Merkel cell carcinoma of the retroperitoneum with no identifiable primary site.

Daniele Rossini; Salvatore Caponnetto; Vittoria Lapadula; Lucilla De Filippis; Gabriella Del Bene; Alessandra Emiliani; Flavia Longo

Merkel cell carcinoma (MCC) is an extremely rare primary neuroendocrine neoplasm of the skin that shows aggressive behavior and a poor prognosis. We report a case of a 67-year-old male with a Merkel cell carcinoma which initially presented itself as a large retroperitoneal mass. Pathological and immunohistochemical analysis revealed tissue consistent with neuroendocrine carcinoma. Despite complete medical workup, no other primary MCC could be detected. While being an atypical presentation, the tumor mass showed an excellent response to the combination of chemotherapy followed by radiotherapy.


Journal of Thoracic Oncology | 2016

94P: First-line treatment with cisplatin plus etoposide for small cell lung cancer and large cell neuroendocrine carcinoma: Our center experience.

G. Del Bene; Arsela Prelaj; J.R. Giròn Berrìos; L. De Filippis; Alessandra Emiliani; A. Galletti; Carla Ferrara; Flavia Longo


European Journal of Cancer | 2017

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in large cell neuroendocrine carcinoma

Arsela Prelaj; Sara Elena Rebuzzi; G. Del Bene; J.R. Giròn Berrìos; Alessandra Emiliani; L. De Filippis; Silvia Pecorari; Alessandra Anna Prete; Gaia Manna; Carla Ferrara; Daniele Rossini; Flavia Longo


Annals of Oncology | 2017

C13Relevance of immunohistochemical (IHC) surrogate reclassification of pT1 breast cancer in luminal-like subtypes: a 15-years long-term observational retrospective study

Alessandra Emiliani; A. Iannace; Gaia Manna; T. Losanno; I. Speranza; F.S. Di Lisa; L. Filomeno; Silvia Pecorari; J R Giron Berios; Patrizia Seminara


Annals of Oncology | 2016

A24Nivolumab in non small cell lung cancer: general and immune-related toxicities in the real life

Alessandra Emiliani; Alessandra Anna Prete; Arsela Prelaj; G. Del Bene; I. Speranza; P. Seminara; Enrico Cortesi; Flavia Longo


Annals of Oncology | 2016

F45The power of traditional prognostic factor and immunohistochemical (IHC) surrogate molecular subtypes of breast cancer (BC) in predicting neoadjuvant chemotherapy response: results of a retrospective study

Gaia Manna; F.S. Di Lisa; I. Speranza; T. Losanno; A. Giuli; Alessandra Emiliani; Alessandra Anna Prete; Arsela Prelaj; Silvia Pecorari; J.R. Giron Berrios; Carmela Fusto; Patrizia Seminara

Collaboration


Dive into the Alessandra Emiliani's collaboration.

Top Co-Authors

Avatar

Gaia Manna

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Arsela Prelaj

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Iannace

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Silvia Pecorari

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Carla Ferrara

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Patrizia Seminara

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Alessio Farcomeni

Sapienza University of Rome

View shared research outputs
Researchain Logo
Decentralizing Knowledge